Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15550220 | 0.79 | LMNA (0.46) | SMN1; SMN2MAPK10NPC1RAB9APKM | |
| SCHEMBL22207115 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPK10NPC1RAB9APKM | |
| SCHEMBL1808824 | 0.79 | — | — | |
| SCHEMBL2629375 | 0.78 | SMYD3 (0.47) | SMN1; SMN2NPC1RAB9APKMLMNA | |
| SCHEMBL25436427 | 0.76 | POLB (0.36) | SMN1; SMN2NPC1RAB9APKMLMNA | |
| SCHEMBL12766570 | 0.76 | MAPK1 (0.43) | SMN1; SMN2MAPK10NPC1RAB9APKM | |
| SCHEMBL5011783 | 0.76 | PKM (0.39) | PKMHDAC6POLBIKBKBCHUK | |
| SCHEMBL22207107 | 0.74 | FPR2 (0.50) | SMN1; SMN2NPC1RAB9AHDAC2HDAC8 | |
| SCHEMBL1674175 | 0.74 | — | — | |
| SCHEMBL15759484 | 0.73 | POLB (0.40) | NPC1RAB9APKMUSP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346573-A1 | AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CHENGDU EASTON BIOPHARMACEUTICALS CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| EP-4534533-A1 | AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) | 2025-04-09 | — | — | EP | disclosed |
| US-20250042901-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2025-02-06 | — | — | US | disclosed |
| US-12139484-B2 | Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| CN-110023290-B | Heteroaryl carboxamide compounds as RIPK2 inhibitors | 勃林格殷格翰国际有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220081437-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2022-03-17 | — | — | US | disclosed |
| EP-3909951-A1 | DIHYDROISOQUINOLINE COMPOUND | Suzhou Ark Biopharmaceutical Co., Ltd (CN) | 2021-11-17 | — | — | EP | disclosed |
| US-11130754-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-28 | — | — | US | disclosed |
| EP-3512833-B1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2020-07-29 | — | — | EP | disclosed |
| WO-2020143604-A1 | DIHYDROISOQUINOLINE COMPOUND | 苏州爱科百发生物医药技术有限公司 | 2020-07-16 | — | — | WO | disclosed |
| EP-3512833-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | Boehringer Ingelheim International GmbH (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-20190048000-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-10138241-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| WO-2018052772-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-22 | — | — | WO | disclosed |
| US-20180072717-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048000-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | SMN1; SMN2 2655/4885MAPK10 971/4885NPC1 1768/4885 |
| US-20180072717-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK3 | SMN1; SMN2 2588/4885MAPK10 939/4885NPC1 1461/4885 |
| US-20250346573-A1 | AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | PARP1, PARP8, PARP11 | SMN1; SMN2 2960/4885MAPK10 3051/4885NPC1 3079/4885 |
| US-10138241-B2 | Substituted benzamides as RIPK2 inhibitors | RIPK2, RIPK4, RIPK1 | SMN1; SMN2 1731/4885MAPK10 1030/4885NPC1 2712/4885 |
| US-20220081437-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK3 | SMN1; SMN2 2588/4885MAPK10 939/4885NPC1 1461/4885 |
| US-11130754-B2 | Substituted benzamides as RIPK2 inhibitors | RIPK2, RIPK4, RIPK1 | SMN1; SMN2 1731/4885MAPK10 1030/4885NPC1 2712/4885 |
| US-20250042901-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | SMN1; SMN2 2655/4885MAPK10 971/4885NPC1 1768/4885 |
| US-12139484-B2 | Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease | RIPK2, RIPK4, RIPK1 | SMN1; SMN2 2990/4885MAPK10 1054/4885NPC1 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.